Show summary Hide summary
Leading specialists in hematology and pediatric care will meet in Hyderabad this week for the GANSID Congress 2026, an international summit that opens Oct. 23 and runs through Oct. 25. The three-day program highlights emerging clinical strategies for inherited blood disorders, with immediate implications for clinicians treating high-risk patients and health systems in regions where sickle cell disease remains endemic.
What to expect at the congress
The Global Action Network for Sickle Cell and Other Inherited Blood Disorders (GANSID) is bringing researchers, clinicians and public-health experts together to present recent trials, case series and care pathways. Organizers say the intent is practical: translate benchside advances into bedside improvements for complex hematologic problems.
Allahabad high court voids three land purchases: woman couldn’t prove continued ST membership
Odissi dazzles at WhiteSwan festival: classical dance wins standing ovations
One session drawing attention will examine the intersection of acute sickle cell complications and thrombotic events—an area where diagnosis and treatment often conflict and outcomes can be severe.
- Dates: Oct. 23–25, 2026
- Location: Hyderabad International Convention Centre
- Notable session: Oct. 24 clinical briefing on recurrent pulmonary embolism in the setting of acute chest syndrome
- Focus: balancing anticoagulation, interventional options and supportive care in fragile pediatric and adult patients
Headline speaker: clinical lessons and global experience
Dr. Aditi Kamdar, a pediatric hematologist affiliated with Baylor College of Medicine and Texas Children’s Hospital, will lead the Oct. 24 briefing. Her presentation, titled “The Clot Thickens: Recurrent Pulmonary Embolism in a Patient with sickle cell disease and acute chest syndrome,” will review a difficult clinical scenario where clotting and respiratory compromise overlap.
Dr. Kamdar’s practice centers on complex bleeding and clotting disorders in children, and she collaborates with interventional teams at Texas Children’s to deploy advanced techniques when patients face life‑threatening thrombosis or hemorrhage. Her talk is expected to cover diagnostic cues, risk stratification and the trade-offs clinicians face when considering anticoagulation during acute chest events.
Beyond her hospital work, Dr. Kamdar has experience delivering care in resource-limited settings: she and her husband, Dr. Mudit Gilotra, spent a year providing frontline medical services in rural Ethiopia, often many hours from the nearest referral center. That background informs her perspective on what is feasible outside major tertiary hospitals.
Why this matters now
As care for inherited blood disorders evolves, clinicians are grappling with new therapies and rising recognition of thrombotic complications in patients with sickle cell disease. Practical guidance from frontline clinicians can change immediate practice—affecting decisions about imaging, anticoagulation, and when to escalate to interventional procedures.
For health systems in South Asia and sub‑Saharan Africa, the meeting is timely: improved diagnostic algorithms and care protocols discussed at GANSID could be adapted to settings with constrained resources, potentially reducing avoidable morbidity and deaths.
Key takeaways clinicians are likely to watch for
- How to detect pulmonary embolism early in patients with overlapping acute chest features.
- Strategies to weigh bleeding risk against clot prevention in acute sickle complications.
- When to use interventional radiology or surgical options for thrombosis in pediatric patients.
- Lessons from delivering care in low-resource environments that can inform broader practice.
The GANSID Congress will also provide a platform for ongoing research collaboration and guideline development. For practitioners, the immediate value lies in actionable clinical guidance; for health planners, the summit offers a view of emerging priorities in managing inherited blood disorders worldwide.
